Enanta Pharmaceuticals
ENTA
121 hedge funds and large institutions have $227M invested in Enanta Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 32 increasing their positions, 43 reducing their positions, and 11 closing their positions.
325% more call options, than puts
Call options by funds: $3.7M | Put options by funds: $870K
127% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 11
63% more capital invested
Capital invested by funds: $139M → $227M (+$87.7M)
13% more funds holding
Funds holding: 107 → 121 (+14)
2.57% more ownership
Funds ownership: 86.28% → 88.84% (+2.6%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
26% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 43
Top Buyers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$11.4M |
| 2 |
CC
Commodore Capital
New York
|
+$6.39M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.4M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$958K |
| 5 |
SC
Stempoint Capital
New York
|
+$601K |
Top Sellers
| 1 |
Marshall Wace
London,
United Kingdom
|
-$4.65M |
| 2 |
Millennium Management
New York
|
-$4.08M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.39M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.35M |
| 5 |
SCM
Sio Capital Management
New York
|
-$1.35M |
ENTA Hedge Fund Activity: Q3 2025 in Review
121 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2025, worth a combined $227M — up 63% from $139M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ENTA positions and 11 closed out — a net gain of 14 holders — while 32 added to existing stakes and 43 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $11.4M. The largest seller was Marshall Wace, cutting an estimated $4.65M.
- 121 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2025, up from 107 in Q2 2025.
- Funds reported $227M of Enanta Pharmaceuticals stock for Q3 2025, up 63% quarter-over-quarter.
- 25 funds opened new Enanta Pharmaceuticals positions in Q3 2025 and 11 closed out, a net change of +14 holders.
- The largest Enanta Pharmaceuticals buyer in Q3 2025 was Janus Henderson Group, an estimated $11.4M added.
- The largest Enanta Pharmaceuticals seller in Q3 2025 was Marshall Wace, an estimated $4.65M sold.
Based on aggregated 13F filings for Q3 2025.